Manhattan Scientifics acquired Senior Scientific in June in order to commercialize innovative nanotechnology tools for detecting, diagnosing, and treating cancer, invented by Dr. Edward R. Flynn. The company has now named V Gerald Grafe to help in the commercialization in a lead role.
The innovative nanotechnology tool has the ability to detect metastases and cancers far earlier than the existing procedure as well as locate and measure cancers more accurately than was possible before. This technology allows for a precise and personalized therapy as it is capable of identifying the correct type of tumor cells present in the body, thereby enabling the surgeon to decide the therapy based on the kind and stage of tumor diagnosed in a patient.
Edward established Senior Scientific to fabricate a nano-electromagnetic sensing technology, particularly for detecting breast cancer prominent in females, where conventional techniques such as mammograms were found to be ineffective. This sensing technology has been clinically proven to measure extremely small tumors comprising 100,000 cells, whereas the mammograms can detect tumors comprising 100,000,000 or more cells. This new tool is suitable for detecting several types of tumors such as brain, pancreatic, ovarian, prostate, breast, and many more. It can detect cancer at the initial stage and also metastases several years before when compared to existing diagnostic methods. It can offer accurate treatment assistance that can avoid further painful and expensive treatments.
The technology developed by Manhattan utilizes magnetic nanoparticles integrated with antibodies to target specific type of tumor cells. The number of tumor cells present in the body can be precisely located and counted by special instruments depending on the introduced nanoparticles coupled with antibodies. The nanoparticles employed are nontoxic; moreover the instrumentation operates without the need for magnetic fields or radiation. The approach can be utilized both for diagnostics and therapeutics.